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Decades after the discovery of natural killer (NK) cells, their developmental pathways in 
mice and humans have not yet been completely deciphered. Accumulating evidence 
indicates that NK cells can develop in multiple tissues throughout the body. Moreover, 
detailed and comprehensive models of NK cell development were proposed soon after 
the turn of the century. However, with the recent identification and characterization of 
other subtypes of innate lymphoid cells (ILCs), which show some overlapping functional 
and phenotypic features with NK cell developmental intermediates, the distinct stages 
through which human NK cells develop from early hematopoietic progenitor cells remain 
unclear. Thus, there is a need to reassess and refine older models of NK cell development 
in the context of new data and in the era of ILCs. Our group has focused on elucidating 
the developmental pathway of human NK cells in secondary lymphoid tissues (SLTs), 
including tonsils and lymph nodes. Here, we provide an update of recent progress that 
has been made with regard to human NK cell development in SLTs, and we discuss 
these new findings in the context of contemporary models of ILC development.
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iNtrODUctiON
Natural killer (NK) cells belong to the family of innate lymphoid cells (ILCs) whose common 
features include reliance on the transcription factor ID2 for development and rapid elaboration of 
effector function in response to microbial products, cytokine stimulation, and contact with other 
leukocytes (1). ILCs share phenotypic and functional features with T cells, yet, ILCs lack expression 
of markers specific for other leukocytes, including antigen-specific T and B cell receptors (i.e., CD3/
TCR and CD19/BCR). In 2013, Spits et al. published a proposal for ILC nomenclature and clas-
sification, including the designation of three major groups according to functional and phenotypic 
characteristics (2). Group 1 ILCs, which express the transcription factor T-BET and produce the 
T helper cell type 1 (Th1)-associated cytokine interferon gamma (IFN-γ), include NK cells as well 
as functionally distinct “ILC1s.” NK cells are unique in their expression of the transcription factor 
EOMES and in their ability to recognize and destroy virally infected and malignantly transformed 
cells that have downregulated major histocompatibility (MHC) class I molecules and/or upregu-
lated stress-induced molecules (3, 4). Group 2 ILCs or “ILC2s” produce Th2-associated cytokines, 
such as interleukin (IL)-5 and IL-13; they express the transcription factors BCL11B, GATA-3, and 
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RORα; and they are involved in many processes, including fat 
metabolism, allergy, and protection against parasites (5). Group 
3 ILCs share features with Th17 cells, including expression of the 
transcription factors AHR and RORγt and production of IL-17 
and IL-22. Group 3 ILCs consist of “ILC3s” as well as lymphoid 
tissue inducer cells whose roles include the formation and 
restoration of lymphoid tissues following infection (6). We refer 
the readers to other excellent comprehensive reviews exploring 
the development, transcriptional regulation, and diverse roles of 
ILCs in physiology and disease (1, 7–12).
As mentioned above, ILCs are identified as “lineage” (Lin) 
negative lymphocytes, lacking expression of surface markers more 
specifically expressed on T cells (CD3, CD5, TCR), B cells (CD19, 
CD20, BCR), myelomonocytic cells (CD14, CD15, CD36), and 
dendritic cells (DCs) (CD116, CD123, CD303). In humans, all 
non-NK ILCs express CD127 (IL-7Rα) and CD161 (NKRP1A) 
(13–16), and they may be further distinguished according to the 
expression of other subset-associated surface antigens includ-
ing CXCR3, CD294 (CRTH2), and CD117 (c-Kit) for ILC1s, 
ILC2s, and ILC3s, respectively (10, 17). Human NK  cells can 
also express the pan-ILC markers CD127 and CD161 (18–20), 
but NK cells are typically distinguished by their surface expres-
sion of CD16 (FcγRIIIA), CD94/NKG2 heterodimers, killer 
immunoglobulin-like receptors (KIRs), NKG2D, and NKp80 
(21). Two subsets of human peripheral blood (PB) NK  cells 
can be distinguished according to their relative expression of 
the pan-NK cell surface marker, CD56 (NCAM-1): “CD56bright” 
and “CD56dim” (22, 23). CD56bright human NK cells express high 
levels of CD62L (l-selectin) and CD94 but absent or low levels 
of CD16 and KIRs; they predominate in secondary lymphoid 
tissues (SLTs) such as lymph nodes (LNs) and tonsils; they show 
low baseline perforin expression and cytotoxic activity ex vivo; 
and they rapidly produce cytokines, including IFN-γ, following 
stimulation by monocyte-derived cytokines (“monokines”), such 
as IL-12, IL-15, and IL-18 (22). In contrast, CD56dim NK cells are 
CD16hi and express more KIRs but less CD94 and CD62L; they 
predominate in PB; they show high baseline perforin expression 
and cytotoxicity against MHC class I negative target cells; and they 
preferentially produce cytokines in response to direct target cell 
interactions rather than via monokine stimulation (3). While the 
developmental relationship between these human NK cell sub-
sets has not been definitively established, evidence suggests that 
CD56bright NK cells represent immediate physiologic precursors of 
CD56dim NK cells (19, 24–29). Alternative hypotheses include that 
CD56bright NK cells represent activated NK cells in vivo and/or that 
PB NK cell subsets derive from distinct hematopoietic progenitor 
cells (HPCs) and developmental pathways (22, 30–33). Recent 
published data from Dunbar and colleagues suggest that the latter 
may be the case in rhesus macaques (34).
HUMAN NK ceLL DeveLOPMeNt iN sLts
Human NK  cells were originally thought to develop strictly 
within the bone marrow (BM) (3, 35). This notion was sup-
ported by the observation that Lin−CD56+ cytotoxic NK  cells 
can be generated in  vitro following culture of purified human 
BM CD34+ HPCs with either BM-derived stroma or with IL-15, 
which can be produced by stroma (36, 37). Nonetheless, more 
recent extensive ex vivo characterization of HPCs and putative 
downstream NK cell developmental intermediates (NKDIs) 
reveals that the latter are naturally enriched in SLTs, including 
tonsils, spleen, and LNs, suggesting that in humans NK cells can 
also, if not preferentially, develop in SLTs (Figure 1A) (38–42). 
Similar NKDIs have also been identified in the thymus, liver, and 
uterus (43–45). Thus, human NK cell development is likely not 
restricted to SLTs (46).
In 2006, five putative stages of human SLT NK cell develop-
ment were described according to the differential expression 
of CD34, CD117, CD94, and CD16 (41, 47, 48). Stage 1 cells 
(Lin−CD34+CD117−CD94−CD16−) lack expression of the com-
mon IL-2/IL-15 receptor beta chain (IL-2/15Rβ, CD122) and are 
thus not responsive to exogenous soluble IL-2 or IL-15 ex vivo. 
However, they can generate NK cells when cultured in IL-15 plus 
other cytokines, such as Flt3 ligand and c-Kit ligand (KL) that 
likely induce CD122 expression and hence IL-15 responsiveness 
(49). In contrast, stage 2 cells (Lin−CD34+CD117+CD94−CD16−) 
constitutively express CD122 (albeit below the level of detec-
tion by flow cytometry) and can generate functionally mature 
NK cells in vitro in the presence of exogenous soluble IL-15 in 
media without other cytokines or support cells (41). Stage 2 cells 
also constitutively express a functional high affinity IL-2 receptor, 
including the IL-2Rα subunit (CD25), and can differentiate in 
response to picomolar concentrations of IL-2 in vitro (39). The 
physiologic relevance of this cytokine receptor expression is not 
yet known and has not been tested in vivo. One likely possibil-
ity is that these HPCs, which are naturally enriched and reside 
within the parafollicular T cell-rich regions of SLTs, can respond 
to T cell-derived IL-2 and differentiate into NK cells following 
T cell activation in vivo (39).
When originally tested in bulk polyclonal cultures under sup-
portive in vitro conditions, stage 1 and stage 2 cells were multipo-
tent and could give rise to T cells and DCs as well as to NK cells, 
although they could not generate B cells or myeloid cells (41). In 
contrast, human stage 3 cells (Lin−CD34−CD117+CD94−CD16−) 
lacked T cell and DC developmental potential. Stage 3 cells could, 
however, give rise to mature NK cells in vitro and in vivo and were 
thus originally proposed to represent committed NK cell precur-
sors (41). Stage 3 cells are distinct from mature NK cells in that 
they lack high expression of T-BET and EOMES, cannot produce 
 IFN-γ, and are incapable of mediating perforin-dependent cyto-
toxicity against MHC class I− target cells. In contrast, these features 
are detected within the stage 4 (CD34−CD117+/−CD94+CD16−) 
and stage 5 (CD34−CD117lo/−CD94+/−CD16+) populations in SLTs 
(40, 41). Stage 5 cells are further distinguished by the constitutive 
expression of CD16, a low affinity receptor for the Fc portion of 
immunoglobulin, which provides for antibody-mediated cellular 
cytotoxicity (50).
receNt ADvANces iN OUr 
UNDerstANDiNG OF HUMAN NKDis
Continued ex vivo phenotypic and functional characteriza-
tion of the aforementioned five putative NKDI populations in 
FiGUre 1 | Ex vivo patterns of surface antigen expression support a model of human natural killer (NK) cell development in secondary lymphoid 
tissues (sLts). (A) Ex vivo immunophenotypic analyses of CD3+ cells (top row, left plots), CD19+ cells (top row, right plots), and Lin−CD56+ cells (bottom row) in 
the indicated tissues demonstrate how immature T, B, and NK cell developmental intermediates (designated by the red circles and ovals) are naturally enriched in 
the thymus, bone marrow, and SLTs, respectively. Of note, the SLT populations designated by the red circles in the bottom row also likely contain some ILC3s, 
which can express CD56 (14). The red arrows in the bottom row highlight the relative enrichment of stage 4b CD56brightNKp80+CD16− NK cells in SLTs. 
(B) Immunophenotypic analysis of Lin− ILCs in human tonsil demonstrating the two-way patterns of CD34, CD117, CD94, NKp80, and CD16 expression as they 
relate to one another. The red arrows depict the putative directions of progressive NK cell development in SLTs. (c) Schematic representation of the proposed 
stages of human NK cell development in SLTs. The stages are defined according to the differential expression of CD34, CD117, interleukin (IL)-1R1, CD94, NKp80, 
CD16, and CD57, and the red lines underline the surface antigen changes that define each stage transition. Although not depicted, it is noted that CD56 
expression is first detected at stage 2b (heterogeneous), peaks at stage 4b (CD56bright), and then decreases to the level of most peripheral blood NK cells at stage 6 
(CD56dim). Also not depicted is killer immunoglobulin-like receptor expression, which is first detected within stage 4b in SLTs (40).
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human SLTs has revealed a remarkable degree of heterogeneity 
within each stage. For example, in a study comparing tonsil- 
and thymus-derived HPCs, McClory et al. demonstrated that 
the human SLT stage 1 population, which expresses CD45RA 
and CD10, contains a minute subset of CD1a+CD11c− cells that 
gives rise to T cells ex vivo and that shows substantial pheno-
typic overlap with CD34+CD45RA+CD10+CD1a+ T cell precur-
sors in the thymus (51). McClory et al. were also able to trace 
a full putative pathway of tonsil T cell development branching 
directly from the tonsil CD34+CD45RA+CD10+CD1a+CD11c− 
stage 1 subset and closely paralleling T cell development in the 
thymus. These data suggest that the developmental pathways 
of other lymphoid subsets overlap/intersect with the origi-
nally characterized NK  cell developmental pathway in SLTs. 
Consistent with this notion, Montaldo et  al. recently showed 
that human SLT-derived stage 2 cells constitutively express 
RORγt and can give rise to RORγt+CD117+ ILC3s (52). In that 
study, Montaldo et al. observed relatively low NK cell produc-
tion from stage 2 cells under the in  vitro conditions tested. 
Given those findings, the investigators concluded that the stage 
2 cells represent lineage-specified ILC3 progenitors. However, 
Montaldo et al. did not assess for the capacity of stage 2 cells 
to differentiate into other lineages such as DCs and T  cells, 
and as mentioned earlier, Freud et al. demonstrated that stage 
2 cells can differentiate into T cells, DCs, and NK cells under 
supportive conditions (41).
In a subsequent study, Scoville et al. characterized two func-
tionally distinct subsets of SLT stage 2 cells according to surface 
expression of the IL-1β receptor, IL-1R1 (42). Both IL-1R1− (i.e., 
stage “2a”) and IL-1R1+ (i.e., stage “2b”) subsets express CD45RA, 
integrin β7, and ID2, and they show low or undetectable expres-
sion of CD10. However, the stage 2b cells are unique in their near 
uniform expression of the pan-ILC marker, CD161, their lack 
of detectable expression of RAG1 mRNA, which is expressed in 
stage 1 and stage 2a cells, and their natural restriction to SLTs. In a 
series of experiments in which stage 1, stage 2a, and stage 2b cells 
were freshly purified and then cultured in vitro or transplanted 
into non-obese diabetic (NOD)-scid IL2Rgammanull (NSG) 
immunodeficient mice treated with human IL-15, the stage 2b 
population was shown to be capable of giving rise to all four major 
subsets of ILCs (ILC1s, ILC2s, ILC3s, and NK  cells), yet, they 
lacked T cell and DC developmental potential. In contrast, stage 
1 and stage 2a cells could give rise to all ILC subsets as well as 
to T cells and DCs under the conditions tested (42). Thus, stage 
2b cells appear to represent common ILC progenitors (CILPs) in 
humans.
Following the original discovery of SLT stage 3 cells 
(41), it was determined that cells within this population 
(Lin−CD34−CD117+CD94−CD16−) express AHR, CD127, 
RORγt, IL-1R1, and IL-22 (14, 53–55). According to the 2013 
ILC classification, these features denote Group 3 ILCs (2). Thus, 
it is not yet clear if stage 3 cells and ILC3s are entirely overlap-
ping in their phenotypic characteristics, and this is a subject of 
ongoing investigation (see below) (56). Within the stage 3/ILC3 
population in human SLTs, there is marked heterogeneity with 
regards to the expression of numerous surface markers, including 
CD7, CD56, CD62L, HLA-DR, and NKp44 (14, 41, 57, 58). The 
significance of this heterogeneity is largely unknown, although it 
was shown that NKp44 expression closely correlates with IL-22 
production ex vivo (53, 58).
Last, in a recent study by Freud and colleagues, the SLT stage 
4 population, defined as Lin−CD34−CD117+/−CD94+CD16−, was 
shown to contain two functionally distinct subsets according to 
expression of the surface activating C-type lectin-like receptor, 
NKp80 (40), which is expressed on most if not all PB NK cells 
in healthy humans (59). Freud et al. described these SLT stage 
4 subsets as stage “4a” (NKp80−) and stage “4b” (NKp80+), and 
they demonstrated that only the stage 4b subset is capable of 
IFN-γ production and perforin-dependent cellular cytotoxicity 
ex vivo (40). Consistent with these functional data, the surface 
expression of NKp80 among total SLT ILCs closely correlates 
with intracellular expression of T-BET, EOMES, and perforin. 
In contrast to stage 4b cells, stage 4a cells, which express CD94/
NKG2A, lack the aforementioned functional and phenotypic 
features associated with mature NK cells and rather show a stage 
3/ILC3-like profile including expression of CD117, CD127, 
IL-1R1, AHR, RORγt, and IL-22 (40). Following co-culture with 
allogeneic monocyte-derived DCs or transplantation into NSG 
mice treated with IL-15, purified SLT stage 4a cells gave rise to 
functional NK  cells including some that were NKp80+CD16+ 
and coexpressed KIRs and CD57, the latter of which has been 
associated with terminal maturation and may represent a putative 
“stage 6” of human NK cell development (60, 61). Thus, stage 4a 
cells appear to comprise a naturally occurring and physiologic 
developmental intermediate population of cells emerging from 
stage 3 cells and giving rise to stage 4b cells. This hypothesis 
is supported by ex vivo patterns of surface antigen expression 
among total Lin− ILCs in human SLTs (Figure 1B).
MODeLiNG HUMAN NK ceLL 
DeveLOPMeNt iN tHe cONteXt AND 
erA OF iLcs
Collectively, these recently published data described above 
support an updated linear model of human NK  cell develop-
ment (Figure  1C), which incorporates SLT NKDIs as well as 
the putative progressive development of human PB NK  cells 
from CD56brightCD94+NKp80+CD16−CD57− (i.e., stage 4b) to 
CD56dimCD94+/−NKp80+CD16+CD57− (i.e., stage 5) to CD56dim 
CD94+/−NKp80+CD16+CD57+ (i.e., stage 6). Although this is 
still somewhat controversial, a linear developmental relationship 
between PB CD56bright and CD56dim NK cell subsets is supported 
by the recent detection of PB NK cell populations that appear to 
represent naturally occurring NKDI spanning the developmental 
continuum between CD56bright and CD56dim NK cells (27, 29). In 
addition, other studies have shown that CD56bright NK cells can 
give rise to CD56dim NK cells in vitro and in vivo (19, 24, 26).
Despite the accumulating evidence in support of this pro-
posed model, it is likely that other pathways of human NK cell 
development exist in  vivo and potentially account for the 
marked diversity among tissue-resident NK  cells (62–64). For 
example, Renoux et  al. recently described a putative lineage 
committed NK  cell progenitor (NKP) population in human 
FiGUre 2 | Models of mouse and human innate lymphoid cell (iLc) development. Shown on the left and right are schematic representations of the cellular 
intermediates and developmental pathways of mouse and human ILCs, respectively. The black lines represent progressive steps of differentiation and maturation 
that are currently supported by published data. The dashed lines represent possible steps and relationships of differentiation and maturation, but these have not yet 
been tested or definitively established. In particular, the relationships between stage 1, 2a, 2b, and 3 cells with NK cell progenitors (NKPs) described by Renoux 
et al. (65) are not yet known. In addition, the relationship and possible distinction between human stage 3 natural killer (NK) cell precursors and ILC3s is also not yet 
clear. In the diagram to the right depicting human ILC development, the labels ILC3P (for ILC3 progenitor), ILC2P (for ILC2 progenitor), and ILC1P (for ILC1 
progenitor) are shown in parentheses to convey that these are theoretical populations that have not been identified. CILP, common innate lymphoid progenitor; 
CHILP, common helper innate lymphoid progenitor.
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BM, blood, and SLTs characterized as Lin–CD34+CD38+CD123– 
CD45RA+CD7+CD10+CD127− and that could only give rise 
to NK  cells in  vitro and in  vivo (65). Given that this NKP is 
only partially CD117+ and reportedly lacks detectable expres-
sion of CD161 and CD127, it appears to be distinct from the 
aforementioned SLT CILP (i.e., stage 2b) population that is 
CD117+CD161+CD127+ and that can generate all ILCs includ-
ing NK  cells (42). Rather, the immunophenotype of the NKP 
described in the study by Renoux et al. appears to overlap with 
that of the stage 1 and stage 2a populations described above. 
Indeed, it will be important in future studies to determine how 
these various HPC populations are related. Regardless, the study 
by Renoux et al. raises the intriguing possibility of other NK cell 
developmental pathways in humans.
It is also important to note that the human model of NK cell 
development depicted here differs from contemporary models of 
murine NK cell development (Figure 2) (1, 7, 12). Aside from 
inherent challenges in comparing these developmental processes 
due to differences in species-specific antigen expression, there 
may be fundamental differences between the species with regards 
to the developmental relationship(s) between NK cells and other 
ILCs and with regards to transcription factor expression patterns. 
For example, in mice, all ILC subsets are thought to derive from a 
CILP population that subsequently gives rise to committed NKPs 
as well as to common helper ILC progenitor cells (CHILPs) that 
can differentiate into ILC1s, ILC2s, and ILC3s, but not NK cells 
(66–70). While putative human CILPs (SLT stage 2b cells) and 
NKPs have been described as discussed above (42, 65), it is not yet 
clear if these two populations are related in the same way that the 
analogous populations in mice have been described. In addition, 
a human CHILP population has not been identified.
Another potential difference between mouse and human 
NK cell development relates to the relationship between NK cells 
and ILC3s. In mice, these two ILC subsets appear to be develop-
mentally distinct (6), because in addition to these CHILP data 
described above, genetic fate-mapping (fm) studies for Rorc2, 
which encodes Rorγt, showed that mouse ILC3s are Rorc2 fm+ 
whereas mouse Eomes+ NK cells are Rorc2 fm− (68, 71, 72). In 
contrast, Scoville et  al. recently demonstrated that the putative 
human CILP (SLT stage 2b) population expresses RORγt and 
that human PB CD56bright NK cells, which are NKp80+EOMES+ 
(4, 40, 59, 73, 74), constitutively express detectable RORC2 tran-
script (42). Thus, as opposed to mouse NK cells, at least some 
human NK cells would be fm+ for RORC2 if such an experiment 
could be performed. In addition, as mentioned earlier, there is 
substantial phenotypic overlap between cells originally described 
as “stage 3” NK cell precursors and cells denoted as “ILC3s” by 
other groups, raising the question as to whether or not these cell 
types are different or comprise the same population in humans 
(56). To address this issue, Crellin et al. previously evaluated the 
6Scoville et al. Human NK Cell Development
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in vitro differentiation potentials of Lin−CD34−CD161+CD117+ 
ILCs according to the differential expression of CD127 (75). They 
demonstrated that a minute CD127− fraction preferentially gave 
rise to NK cells whereas the predominant CD127+ fraction mostly 
retained ILC3 features. Thus CD127 has since been touted as a 
critical marker distinguishing human stage 3 NK cell precursors 
from ILC3s (1, 6). However, in the study by Crellin et al., CD94+ 
NK cells, which can express CD117 and CD161 (18, 76), were not 
excluded in the pre-culture sorting preparations (75). Moreover, 
other reports suggest that the in vitro conditions used by Crellin 
et al. may be better optimized for supporting NK cell differentia-
tion; conditions such as co-culture with OP9-DL1 stroma or DCs 
may be needed (40, 42). As such, the results provided in the Crellin 
et al. study could be due at least in part to the culture conditions 
employed and/or the preferential expansion of CD94+ NK cells that 
were present in the sorted Lin−CD34−CD161+CD117+CD127− 
fractions. Last, we note that CD127 is constitutively expressed on 
PB CD56bright NK cells (19, 20), and so excluding any CD127+ cells 
as potential NK cell precursors may be incorrect. Thus, to the best 
of our knowledge, there is as yet no reliable immunophenotypic 
strategy to distinguish human stage 3 NK cell precursors from 
ILC3s. Further investigation is needed.
cONcLUDiNG reMArKs AND FUtUre 
DirectiONs
The goals of investigating human NK  cell development are to 
understand malignant counterparts and to facilitate the design 
and implementation of optimal immunotherapies for patients 
with cancer and potentially other diseases. Much progress has 
been made; however, the recent discovery of non-NK ILCs has 
required a reassessment of models of NK  cell development in 
both mice and humans. More work is also needed in order to 
understand how all ILCs develop and to determine if the putative 
pathway of human NK cell development in SLTs is representative 
of NK cell development in other tissues.
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